Grifols S.A. American Depositary Shares (GRFS) fair value

ACCE thesis

Grifols makes plasma-derived therapies (immunoglobulins, albumin, clotting factors) collected from donor centres and sold to hospitals and specialty pharmacies, and it is one of the few companies with a vertically integrated collection network at that scale. That network is hard to replicate and gives the business durable supply advantages in a market where plasma is the bottleneck. Revenue is flat to slightly down (-0.9%) and ROE is only 6.9%, so the thesis rests on margins holding up (gross 37.8%, operating 15.9%) rather than on top-line momentum. At 9.3x trailing and 5.8x forward earnings the stock screens cheaply against those margins, but a forward multiple that far below trailing implies analysts expect a sharp earnings step-up, and that expectation is the key thing to test. The name is a 55/100 on our scoring and sits in the Fair Value Leaders universe, so it merits a deeper look at the earnings bridge and plasma collection volumes before any view is formed.